Breaking News, Collaborations & Alliances

BMS, Lilly Evaluate Combo Cancer Treatment

To evaluate nivolumab in combination with Lilly’s galunisertib

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb and Eli Lilly have entered a clinical trial collaboration to evaluate the safety and efficacy of BMS’ immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299) as a potential treatment for advanced glioblastoma, hepatocellular carcinoma, and non-small cell lung cancer. Lilly will conduct the trials. Additional details were not disclosed.   Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expres...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters